COMMUNIQUÉS West-GlobeNewswire

Strongbridge Biopharma plc Presents Detailed Initial Results from Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 18th Annual Congress of the European NeuroEndocrine Association
22/10/2018
~ As Previously Reported, SONICS Met its Primary Endpoint With 30 Percent of the ITT Patient Population Reaching & Maintaining Mean Urinary Free Cortisol (mUFC) Normalization Following Six Months of Maintenance [...]
BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress
22/10/2018
CAMBRIDGE, Mass. and BEIJING, China, Oct. 22, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Myriad’s BRACAnalysis CDx® Test Identifies Patients with Newly Diagnosed Advanced Ovarian Cancer Who May Benefit from Maintenance Treatment with Lynparza®
22/10/2018
SALT LAKE CITY, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx ® test accurately identified [...]
Helius Medical Technologies Receives Medical Device License Clearance from Health Canada for PoNS™ Device
22/10/2018
NEWTOWN, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its wholly [...]
Ultragenyx Announces Exclusive License to REGENXBIO AAV Vectors to Develop Gene Therapy for CDD (CDKL5 Deficiency Disorder)
22/10/2018
Ultragenyx CEO to present Keynote Address at the 2018 CDKL5 Forum hosted by the Loulou Foundation NOVATO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical [...]
ICU Medical, Inc. Announces Time of Third Quarter 2018 Earnings Conference Call
22/10/2018
SAN CLEMENTE, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care [...]
Breathtec Announces Acquisition of Nash Pharmaceuticals
22/10/2018
VANCOUVER, British Columbia, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: BTH ) (FRANKFURT: BTI) (OTCQB: BTHCF ) (the “ Company ” or “ Breathtec ”) is pleased to announce that further [...]
Capricor Therapeutics to Participate in Upcoming Conferences
22/10/2018
Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy Therapies LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc . (NASDAQ: CAPR), is [...]
Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018
22/10/2018
- Pelareorep more than doubles overall survival at recommended phase two dose as compared to historical phase 3 data - CALGARY, Alberta and SAN DIEGO, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ [...]
Kamada Announces Appointment of Life Sciences Industry Executive Eitan Kyiet as Vice President of Business Development
22/10/2018
REHOVOT, Israel, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Eitan Kyiet as Vice President of Business [...]
Auxly Announces Cultivation and Retail Expansion Into Newfoundland & Labrador Through Strategic Partnership With Atlantic Cultivation
22/10/2018
VANCOUVER, British Columbia, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (" Auxly " or the " Company ") is pleased to announce that the Company has entered into a binding [...]
Quark Pharmaceuticals Announces Acceptance of Presentation and Abstracts at ASN 2018 (October 23-28, 2018) and AAO 2018 (October 27-30, 2018) Annual Meetings
22/10/2018
FREMONT, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical [...]
New Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients
22/10/2018
SINGAPORE, Oct. 22, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in [...]
ESMO 2018: Athenex Presented Encouraging Clinical Trial Efficacy and Safety Results of Oraxol in the Treatment of Metastatic Breast Cancer
22/10/2018
BUFFALO, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer [...]
Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018
22/10/2018
Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an [...]
CytomX Therapeutics Presents Clinical Data from Probody™ Platform and CX-072 at 2018 ESMO Annual Meeting
22/10/2018
- Additional Data Supports PD-L1 Targeting Probody CX-072 as Well Tolerated with Antitumor Activity as Monotherapy and in Combination with Ipilimumab - - Company to Host Conference Call and Webcast Today, Monday, [...]
NICE publishes advice on gammaCore for the treatment of cluster headache
22/10/2018
Report contributors agreed gammaCore was innovative and it has the potential to save money through the NHS by reducing the cost of treating cluster headache BASKING RIDGE, N.J., Oct. 22, 2018 (GLOBE NEWSWIRE) -- [...]
AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence
22/10/2018
Lausanne, Switzerland, October 22, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Dr. [...]
Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
22/10/2018
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of patients who may not relapse [...]

Pages